Pomerantz LLP is investigating claims on behalf of investors of Rubius Therapeutics, Inc. Such investors are advised to contact Robert S. Willoughby at firstname.lastname@example.org or 888-476-6529, ext. 7980.
The investigation concerns whether Rubius and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
On April 8, 2022, Rubius issued a press release “Report[ing] Updated Clinical Data at AACR from the Ongoing Monotherapy Phase 1 Arm of the Phase 1/2 Clinical Trial of RTX-240 in Advanced Solid Tumors.” Although Rubius touted that the data demonstrated “single-agent activity and favorable tolerability,” the data appeared to be less effective than its previous readout.
On this news, Rubius’s stock price fell $2.67 per share, or 45.56%, to close at $3.19 per share on April 8, 2022.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Robert S. Willoughby
888-476-6529 ext. 7980